1717 K Street NW, Suite 900

Washington, DC 20006-5349

(877) 363-6376

HELPLINE

NEWS

2020 mesothelioma research grant cycle opens — LOIs due Nov. 1

DNA Genotyping and Sequencing

The Mesothelioma Applied Research Foundation’s 2020 mesothelioma research grant cycle is now accepting pre-application letters of intent (LOI) until 11:59 PM ET Sunday, Nov. 1, 2020 on proposalCENTRAL. Our research grant program offers $100,000 grants for two years ($50,000 per year).

Please read the below before accessing the application portal and template on proposalCENTRAL.

Who Can Apply:
  • Investigators who have a doctoral-level degree and a full-time faculty position or equivalent at a college, university, medical school, or eligible not-for-profit research organization globally. 
  • Junior investigators with an interest in a carrier focus in mesothelioma are strongly encouraged to apply to this RFA. As part of their application, they should identify an established mesothelioma researcher as their mentor and provide a career development and mentorship plan in the context of their application.
Additional information to be included in the LOI:
  • All applications need to focus on pleural and/or peritoneal mesothelioma and should address at least one of the 2020 Areas of Interest (listed below).
  • All projects must be feasible within the timeline and budgetary constraints of the current RFA.
  • All other funding, overlapping and/or supplemental funding, for the proposed project should be disclosed as part of the application.
2020 Areas of Interest:
  • Novel therapies for mesothelioma for both pleural and peritoneal (focus on – targeted therapies, combination immunotherapy, cellular therapy, virotherapy)
  • Novel strategies for screening and early detection
  • Immune mediated complications of immunotherapy in mesothelioma (monitoring, early detection and management)
  • Improving personalization of therapies (gender and racial differences, targeted therapies and predictive biomarkers)
  • Mechanisms of treatment resistance/failure
  • Improvement Quality of life in mesothelioma patients (treatment related /toxicities and survivorship issues)
  • Improvement of Mental Health in mesothelioma patients
  • Mesothelioma Biology and Etiology (disease-defining molecular pathways, cellular biology, and/or tumor microenvironment)

For questions, please contact Jordan Fingerhut, Patient and Grants Program Senior Associate, at [email protected] or 703-879-3824.

Also...

In Other News

Share:

Facebook
Twitter
LinkedIn